Unstable angina
Conditions
Interventions
treat:xueshuantong 500mg IV drip
control:xueshuantong 25mg IV drip
Sponsors
Xiyuan Hospital China Academy of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: Those who meet all of the following criteria are eligible for inclusion in this study (1) Meet the diagnosis of coronary heart disease and meet at least one of the following diagnostic criteria: 1) have previously The history of myocardial infarction was confirmed. 2) coronary artery revascularization and 3) coronary angiography were performed Or coronary angiography results indicate at least one coronary artery stenosis with lumen stenosis = Cardiac magnetic resonance imaging or nuclide myocardial perfusion imaging confirmed coronary myocardial ischemia in 50% This; (2) Meet the diagnosis of unstable angina pectoris and have at least one of the following conditions A transient or persistent ST segment shift of 0.1mV or more on one or more leads 2)TIMI risk score =3 (see Annex 2: TIMI risk score); (3) Currently receiving dual antiplatelet therapy; (4) Pre-elderly patients 45-64 years old elderly patients 65-75 years old gender is not limited; (5) TCM syndrome is blood blood stasis; (6) Hospitalized patients voluntarily receiving the drug and signing informed consent. Informed consent The process complies with the relevant provisions of GCP.
Exclusion criteria
Exclusion criteria: Those with any of the following criteria were not included in the study (1) Patients with grade IV heart function; Or unstable angina pectoris short-term risk stratification is high risk Patients at risk; (2) With uncontrolled grade III hypertension (systolic blood pressure =180mmHg and/or diastolic blood pressure =180 MMHG 110mmHg) severe cardiopulmonary insufficiency severe arrhythmia liver kidney and hematopoietic Patients with serious primary diseases such as systemic diseases or serious diseases that affect their survival (such as tumors) And the mentally ill; (3) Combined with other clinical conditions that may increase the risk of bleeding such as important organs in the past six months Bleeding history (such as cerebral hemorrhage upper gastrointestinal hemorrhage etc.) decreased platelet count coagulation function Abnormal recent active bleeding etc.; ? Abnormal liver and kidney function indicators (ALT and AST exceed the upper limit of the normal reference range 2 Times GFR < 60 ml/min•1.73m2); Simplified MDRD formula: GFR [ml/ (min •1.73m2)]=186.3× (Scr) -1.154× (age) -0.203× (0.742) Female); Scr: mg/dl age: years. (5) Those who plan to undergo revascularization (PCI or CABG) in the near future; (6) Allergy or food allergy to multiple drugs or known allergy to study drugs (including Prescription ingredients) allergic patients; ? A woman who is pregnant or preparing to become pregnant or breastfeeding; (8) Patients who have participated in other clinical studies within the last 1 month; (9) Participants considered unsuitable for clinical trials by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cathepsin K;Creatine Kinase-Myocardial Band;Lectin-like oxidized low-density lipoprotein receptor-1;cardiac Troponin T;N-terminal pro-B-type natriuretic peptide; | — |
Secondary
| Measure | Time frame |
|---|---|
| Seattle Angina Questionnaire(SAQ); | — |
Countries
China
Contacts
Public ContactLiumi
Xiyuan Hospital China Academy of Traditional Chinese Medicine
Outcome results
None listed